Proteome analysis and its impact on the discovery of serological tumor markers

Clinica Chimica Acta

Volumn 313, Issue 1-2, 2001, Pages 231-239

  Poon, Terence C W ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Malignancy; Proteome; Proteomics; Serum; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; PROTEOME; TUMOR MARKER;

CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEROLOGY; TECHNIQUE;

CARCINOMA, HEPATOCELLULAR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; LIVER NEOPLASMS; MASS SPECTROMETRY; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034748668     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00677-5     Document Type: Conference Paper

References (43)

1. Tumor markers in malignancies
2. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it
3. From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and amino acid analysis
4. Proteomics: Quantitative and physical mapping of cellular proteins
5. Proteomics: Applications in basic and applied biology
6. Comprehensive two-dimensional high-performance liquid chromatography for the isolation of overexpressed proteins and proteome mapping
7. Characterization of proteins from human cerebrospinal fluid by a combination of preparative two-dimensional liquid-phase electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
8. On-line coupling of high-performance liquid chromatography with imaged capillary isoelectric focusing using a membrane interface
9. Proteome analysis of mouse brain: Two-dimensional electrophoresis profiles of tissue proteins during the course of aging
10. Two-dimensional database of mouse liver proteins: Changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol
11. Tracking pathology with proteomics: Identification of in vivo degradation products of alphaB-crystallin
12. Proteomics meets cell biology: The establishment of subcellular proteomes
13. Identifying the proteome: Software tools
14. Micropreparative two-dimensional electrophoresis allowing the separation of samples containing milligram amounts of proteins
15. Advances in protein solubilisation for two-dimensional electrophoresis
16. Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels
17. Towards high performance two-dimensional gel electrophoresis using ultrazoom gels
18. High-throughput profiling of the mitochondrial proteome using affinity fractionation and automation
19. Large-gel 2D electrophoresis
20. Proteome analysis of glycoforms: A review of strategies for the microcharacterisation of glycoproteins separated by two-dimensional polyacrylamide gel electrophoresis
21. Mass spectrometric characterization of stathmin isoforms separated by 2D PAGE
22. Linking genome and proteome by mass spectrometry: Large-scale identification of yeast proteins from two-dimensional gels
23. Two-dimensional electrophoresis map of human hepatocellular carcinoma cell line, HCC-M, and identification of the separated proteins by mass spectrometry
24. Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumor necrosis factor alpha or the peroxisome proliferator nafenopin
25. Functional genomics by mass spectrometry
26. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias
27. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma
28. Primary mediastinal malignant germ cell tumor. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends
29. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels
30. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma
31. Cirrhosis and the aetiology of hepatocellular carcinoma
32. Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography
33. Primary malignant neoplasms of the liver: Detection with helical CT during arterial portography
34. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
35. Bladder squamous cell carcinoma biomarkers derived from proteomics
36. Analysis of polypeptide expression in benign and malignant human breast lesions: Down-regulation of cytokeratins
37. Renal cell carcinoma and normal kidney protein expression
38. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis
39. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease
40. A clinical study of complements as a marker of hepatocellular carcinoma
41. Serum copper and ceruloplasmin in early and in advanced hepatocellular carcinoma: Diagnostic and prognostic relevance
42. Direct analysis of protein complexes using mass spectrometry
43. Quantitative analysis of protein mixtures using isotope coded affinity tags